Covid-19 Impact on CAR-T Cell Therapy Clinical Trial for the Patients Suffering from DLBCL

Release Date: 16-Nov-2020

Covid-19 is the ongoing pandemic at global level with no cure, therefore, researchers across the globe are now focused towards developing an efficient treatment for the disease. Researchers from Levine Cancer Institute are oriented towards evaluating the effect coronavirus disease 2019 (COVID-19) had on using chimeric antigen receptor (CAR) T-cell therapy to treat patients with diffuse large B-cell lymphoma (DLBCL).

It was concluded at the starting of the pandemic that it would impact the ongoing CAR-T cell therapy as well as the stem cell transplants also. Some of the CAR T-cell treatment therapies that are available for the patients suffering from diffuse large B-cell lymphoma (DLBCL) are axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah). With the start of the pandemic at global level, lots of uncertainty was developed with respect to the acute cases, intensive care units and hospital beds

With the passing time, the researchers and the physicians started treating the patients suffering from Covid-19 as a new normal. It was stated by the researchers working on the CAR-T cell therapy that they will focus on not majorly affecting the delivery of CAR T-cell therapy for clinical trials and treatment with standard of care in practices. The researchers from the starting of the pandemic have been trying their best to deliver the best possible standard-of-care for the patients who were undergoing CAR-T therapy. Although in the starting of the pandemic i.e. first few months of the pandemic all the clinical trials with respect to the CAR-T cell therapy were halted but now all the clinical trials have opened back.